Every 8-K that BioRestorative Therapies, Inc. (BRTX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow BRTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BRTX filings page.
BioRestorative Therapies, Inc. appointed Donald J. Currie as a Class I director effective immediately on October 7, 2026, filling the vacancy created by Katharyn Field’s resignation effective August 31, 2026. He will serve until the Company’s 2027 annual meeting and until his successor is elected and qualified, or his earlier death, resignation or removal.
The Board also appointed Currie to the Compensation Committee and the Nominating and Corporate Governance Committee, and determined that he is an independent director under Nasdaq listing rules. He will receive a CAD $2,000 monthly cash fee, payable monthly in arrears, and reimbursement for reasonable out-of-pocket expenses; he will not participate in the standard non-employee director compensation program. The Company expects to enter into an indemnification agreement with him.
BioRestorative Therapies, Inc. (BRTX) reported that on September 4, 2026, Vice President of Research and Development Mr. Silva resigned from his employment and all officer positions, effective immediately. His notice states that the resignation is for “Good Reason” under an Executive Employment Agreement he asserts was entered into and later amended, tied to an alleged “Change in Control” following Board changes associated with a Revolving Loan Agreement with Bowery Group LLC. Mr. Silva is asserting entitlement to approximately $1.29 million in cash severance, acceleration of equity awards and continued benefits if the agreement is deemed valid and his resignation qualifies as “Good Reason.” The Board has acknowledged the resignation for record-keeping purposes but expressly disputes the validity and effect of the Employment Agreement and the characterizations in the notice, and the Company has reserved all rights, claims and defenses. The Board previously authorized an investigation by special counsel into the negotiation, approval, execution and amendment of this and similar executive employment agreements and has determined that, pending completion of that investigation and further Board action, no payments or benefits will be made under the Employment Agreement other than accrued base salary and amounts required by wage-payment law.
BioRestorative Therapies, Inc. (BRTX) filed an amended current report describing a change in independent auditors and an ongoing review related to its suspended biocosmeceutical product lines. On August 28, 2026, the company dismissed CBIZ CPAs P.C. as its independent registered public accounting firm, a decision approved by the Board on August 26, 2026 and ratified by the Audit Committee on September 1, 2026. CBIZ’s report on the fiscal year ended December 31, 2025 contained an explanatory paragraph expressing substantial doubt about the company’s ability to continue as a going concern, but no adverse or disclaimed opinion and no scope or accounting qualification.
CBIZ informed the company that a “reportable event” may exist because the previously disclosed suspension of ExoCR and BioX product lines and related reviews could, if further investigated, potentially affect the reliability of previously issued financial statements, though CBIZ has not identified any such impact or advised that prior statements should not be relied upon. Effective August 28, 2026, BioRestorative engaged Bush & Associates CPA as its new independent registered public accounting firm for 2026 and to perform new audits of 2025 and 2024. The Audit Committee has also hired an independent investigator; to date no previously unreported material information has been uncovered, and the investigation and business and regulatory reviews remain ongoing.
BioRestorative Therapies, Inc. (BRTX) is implementing a 1-for-20 reverse stock split of its common stock, effective at 4:30 p.m. Eastern Time on September 7, 2026. Every 20 shares outstanding immediately before the effective time will be automatically combined and reclassified into 1 share, with no change to par value.
Shares outstanding will be reduced from 27,622,556 to approximately 1,381,128, and authorized common shares will decrease proportionately from 1,500,000,000 to 75,000,000; authorized preferred shares remain at 20,000,000. Fractional positions will be rounded up so each affected holder receives one whole share, and percentage ownership will be unchanged aside from de minimis fractional adjustments.
The common stock will begin trading on a reverse split–adjusted basis on the Nasdaq Capital Market on September 8, 2026 under the symbol BRTX and a new CUSIP. The company states it is effecting the reverse split with the intention of regaining compliance with Nasdaq’s $1.00 minimum bid price continued listing requirement.
BioRestorative Therapies, Inc. (BRTX) reports a change in auditor and several leadership transitions. The company dismissed CBIZ CPAs P.C. as independent registered public accounting firm effective August 28, 2026, after CBIZ’s report on the year ended December 31, 2025 included an explanatory paragraph expressing substantial doubt about the company’s ability to continue as a going concern, though there were no disagreements or reportable events. Bush & Associates CPA was engaged as the new auditor for the 2026 fiscal year.
The board accepted the transition of Katharyn Field from Interim CEO, CFO, Treasurer and Secretary and her resignation as a director, and appointed director Mika Grasso as Interim CEO effective August 26, 2026 and Anna Skowron as non-employee, fractional Chief Financial Officer and Treasurer effective August 27, 2026. Both Mr. Grasso and Ms. Skowron will serve under consulting agreements, with monthly fees and eligibility for incentive and equity-based compensation. The board also reconstituted its committees and approved indemnification agreements for Grasso, Skowron and Field.
BioRestorative Therapies, Inc. (BRTX) reports receiving a delinquency notification letter from Nasdaq on August 21, 2026 because it did not timely file its Form 10‑Q for the quarter ended June 30, 2026, putting it out of compliance with Nasdaq Listing Rule 5250(c)(1). The company’s common stock continues to trade on the Nasdaq Capital Market under the symbol BRTX, and the notice has no immediate effect on the listing. BioRestorative Therapies has until October 20, 2026 to submit a plan to regain compliance; if Nasdaq accepts the plan, it may grant an exception of up to 180 days from the Form 10‑Q due date, through February 16, 2027. If Nasdaq does not accept the plan, the company may appeal to a Nasdaq Hearings Panel. The company states it is working to complete and file the Form 10‑Q and to submit a compliance plan.
BioRestorative Therapies, Inc. reported that on August 7, 2026 it suspended, effective immediately, all orders and shipments of its biocosmeceutical product lines, including its ExoCR and BioX products, pending a business review and regulatory assessment. The company stated it has not decided to discontinue these product lines and is reviewing documentation, sourcing, and the regulatory status associated with them. The company noted that outcomes of this review, its ability to resume sales, related costs, and its capital needs are subject to significant risks and uncertainties described in its prior SEC reports.
Biorestorative Therapies, Inc. amended executive employment agreements on July 8, 2026 so that cash severance and accelerated equity vesting are triggered only by a Change in Control involving a reorganization, merger, consolidation or sale of all or substantially all assets, rather than also by changes in share ownership or board composition.
Director David Rosa resigned on July 11, followed on July 13 by President, CEO and Chair Lance Alstodt and CFO Robert Kristal, who resigned and claimed Good Reason based on an asserted Change in Control tied to prior board changes. If their resignations were determined to be for Good Reason, they would claim approximately $2.85 million in aggregate cash severance, accelerated equity and continued benefits. The board has recorded the resignations but disputes that a Change in Control or Good Reason occurred, has initiated an investigation by special counsel into the employment agreements, and is withholding any severance or related benefits pending its outcome.
Effective July 13, 2026, director Katharyn Field was appointed Chief Executive Officer, President and interim Chief Financial Officer, Treasurer and Secretary, becoming the principal executive, financial and accounting officer. The board also elected independent directors Esha Randhawa (Class II, term to the 2028 annual meeting) and Steven Brown (Class III, term to the 2026 annual meeting), redesignated committee roles, and confirmed its audit committee financial expert.
BioRestorative Therapies, Inc. has entered into a new executive employment agreement with Francisco Silva, its Vice President of Research and Development, effective June 10, 2026, with a term running through June 10, 2029 and automatic one-year renewals thereafter.
Silva will receive a base salary of $575,000, eligibility for an annual cash bonus of up to 50% of salary, four weeks of vacation, and potential annual stock option grants under the 2021 Stock Incentive Plan. If he is terminated without Cause or resigns for Good Reason, he is entitled to 1.5 times the sum of salary and maximum bonus, 1.5 years of COBRA premiums paid by the company (subject to conditions), and full vesting of outstanding equity awards. A Change in Control of specified types also triggers payment of this cash severance and full equity vesting. The agreement includes confidentiality, invention assignment, and a one-year non-compete and non-solicitation covenant following termination.
BioRestorative Therapies, Inc. entered into a Revolving Loan Agreement with Bowery Group LLC, giving it the ability to draw up to $1,000,000 in revolving loans for general corporate purposes. The associated Revolving Promissory Note carries a 12% annual interest rate, rising to 16% on outstanding principal after an Event of Default, with each loan maturing one year after its closing.
The financing is tied to significant board changes. Effective June 11, 2026, three directors resigned under the agreement, and on June 12, 2026, three new lender-designated independent directors — Mika Grasso, Katharyn Field and Jatinder Dhaliwal — were appointed to the board and its key committees. The company states that each new director meets Nasdaq independence standards, and Grasso is designated as an audit committee financial expert.
BioRestorative Therapies, Inc. reported two key corporate actions. Stockholders approved an amendment to its Articles of Incorporation increasing authorized common shares from 75,000,000 to 1,500,000,000, with 9,868,606 votes for, 2,389,059 against and 179,207 abstentions.
The company also entered into new three-year employment agreements, through May 27, 2029, with CEO/Chairman/President Lance Alstodt and CFO Robert Kristal. Alstodt’s annual salary is $600,000 with an annual bonus opportunity up to 50% of salary, while Kristal’s annual salary is $350,000 with a bonus opportunity up to 40%. Both contracts include severance and accelerated equity vesting protections upon certain terminations and specified Change in Control events.
BioRestorative Therapies, Inc. reported that its Compensation Committee approved cash bonuses for executive officers for the year ended December 31, 2025, and presented an updated Summary Compensation Table.
For 2025, CEO Lance Alstodt received salary of $596,666, a discretionary cash bonus of $300,000 and total compensation of $2,409,167. VP of Research and Development Francisco Silva received salary of $566,666, a $287,500 discretionary bonus and total compensation of $2,322,916. CFO Robert Kristal received salary of $343,750, a $140,000 discretionary bonus and total compensation of $801,750. The bonuses relate to 2025 services and are to be paid in 2026.
BioRestorative Therapies, Inc. furnished an updated corporate presentation that may be used at conferences and investor meetings. The deck is available on the company’s website and is attached as Exhibit 99.1.
The presentation is furnished under a disclosure item and is not deemed filed or subject to Section 18 liability, nor automatically incorporated into other Securities Act or Exchange Act filings.
BioRestorative Therapies, Inc. completed a public offering of 14,285,715 shares of common stock (or pre-funded warrants in lieu thereof) and accompanying warrants, raising approximately $5.0 million in gross proceeds at a price of $0.35 per share or pre-funded warrant and warrant.
Each warrant is immediately exercisable at $0.35 per share and expires five years from issuance. The company plans to use the net proceeds to fund clinical trials for its BRTX-100 disc/spine program, pre-clinical work on its ThermoStem metabolic program, expand its BioCosmeceuticals platform, and for general corporate purposes and working capital.
Rodman & Renshaw LLC acted as exclusive placement agent and received a 7.0% cash fee on gross proceeds, expense reimbursement of up to $100,000, and five-year placement agent warrants for 350,000 shares at an exercise price of $0.4375 per share.
BioRestorative Therapies, Inc. filed a current report to note that it issued a press release on November 12, 2025 announcing its financial results for the third quarter ended September 30, 2025. The release also includes a broader business update and information about a conference call to discuss the quarter.
The press release is furnished as Exhibit 99.1 and, as the company emphasizes, is provided under the rules for furnished, not filed, information. That means it is not automatically subject to certain Exchange Act liabilities and will only be incorporated into other SEC filings if specifically referenced.
BioRestorative Therapies, Inc. entered into subscription agreements for a registered direct offering of 678,125 common shares at $1.60 per share, for gross proceeds of $1.085 million before fees. In a concurrent private placement, investors receive unregistered warrants to purchase up to 508,592 additional shares at an exercise price of $2.75.
The company plans to use net proceeds to fund clinical trials for its BRTX-100 cell therapy, pre-clinical work on its ThermoStem metabolic program, development of a commercial biocosmeceuticals platform, and for general corporate purposes and working capital. The unregistered warrants are exercisable six months after issuance for five years, include a 4.99% beneficial ownership cap, allow cashless exercise if no resale registration is effective, and may be redeemed by the company for $1.00 per warrant if the stock trades above $5.00 for ten consecutive trading days. A placement agent will receive cash fees, expense reimbursement and a warrant based on a percentage of shares sold.
BioRestorative Therapies, Inc. reported the results of its Annual Meeting of Stockholders held on September 18, 2025. Stockholders elected Class II directors Francisco Silva and David Rosa, each receiving over 1.47 million votes in favor, with more than 3.32 million broker non-votes recorded for each nominee.
Stockholders also approved an amendment to the 2021 Stock Incentive Plan to increase the number of shares of common stock authorized under the plan from 6,850,000 to 9,850,000. In addition, they ratified the selection of CBIZ CPAs P.C. as independent registered public accounting firm for the fiscal year ending December 31, 2025, and approved, on a non-binding advisory basis, the compensation of the Company’s executive officers.
BioRestorative Therapies, Inc. filed a current report to let investors know it has made an updated corporate presentation available. The presentation may be used at conferences and investor meetings and is accessible on the company’s website as well as attached as Exhibit 99.1. The company specifies that this presentation is being furnished under a disclosure item rather than formally filed, meaning it is not subject to certain Exchange Act liability provisions and is not automatically incorporated into other securities filings unless specifically referenced.
BioRestorative Therapies, Inc. furnished a press release announcing its financial results for the quarter ended June 30, 2025. The release also provided a business update and included details for a conference call to discuss the quarter. A copy of the press release is furnished as Exhibit 99.1 to this Current Report.
The filing states that the information furnished is summary information to be considered in the context of the Company’s SEC filings and other public announcements. The Company expressly furnishes the press release (it is not being filed for purposes of Section 18 of the Exchange Act) and does not incorporate the press release by reference into other registration statements unless specifically stated.